Wed, Jul 23, 2014, 10:24 AM EDT - U.S. Markets close in 5 hrs 36 mins

Recent

% | $
Click the to save as a favorite.

Celgene Corp. (CELG) Message Board

  • big_pharma_coming big_pharma_coming Nov 27, 2011 3:19 PM Flag

    9 pom ASH presentations-amazing interim to final jump in RR w/ 100 more patients

    Rodman & Renshaw - 9 Selected Pomalidomide 2011 ASH Abstracts

    Monday 3:00 PM Ballroom 20D 632

    A Phase I/II Study of Pomalidomide-Cyclophosphamide-Prednisone (PCP) in Patients with Multiple Myeloma Relapsed/Refractory to Lenalidomide
    Oral A. Palumbo Pomalidomide Celgene

    Monday 3:30PM Ballroom 20D 634
    Randomized, Open Label Phase 1/2 Study of Pomalidomide (POM) Alone or in Combination with Low-Dose Dexamethasone (LoDex) in Patients (Pts) with Relapsed and Refractory Multiple Myeloma Who Have Received Prior
    Treatment That Includes Lenalidomide (LEN) and Bortezomib (BORT): Phase 2 Results
    Oral P. Richardson Pomalidomide Celgene

    Monday 3:45 PM Ballroom 20D 635
    ClaPD (Clarithromycin/[Biaxin®], Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma
    Oral T. Mark Pomalidomide Celgene

    Monday 4:45 PM Ballroom 20D 812
    High Response Rates to Pomalidomide and Dexamethasone in Patients with Refractory Myeloma, Final Analysis of IFM 2009-02
    Oral X. Leleu Pomalidomide Celgene

    Saturday
    5:30 PM - 7:30 PM
    Hall GH 1757
    Phase II Study of Low-Dose Pomalidomide in Patients with Myelofibrosis and Significant Anemia (hemoglobin <10g/dL)
    Poster A. Shastri Pomalidomide Celgene

    Saturday
    5:30 PM - 7:30 PM
    Hall GH 1759
    Pomalidomide Therapy for Myelofibrosis: Analysis of Results From Three Consecutive Clinical Trials
    Poster K. Begna Pomalidomide Celgene

    Saturday
    5:30 PM - 7:30 PM
    Hall GH 1881
    Simulation of Clinical Outcome for Pomalidomide Plus Low-Dose
    Dexamethasone in Patients with Refractory Multiple Myeloma Based on
    Week 8 M-Protein Response
    Poster H. Bruno Pomalidomide Celgene

    Monday
    6:00 PM - 8:00 PM
    Hall GH 2942
    Long Term Outcomes of Pomalidomide and Dexamethasone in Patients with Relapsed Multiple Myeloma: Analysis 4 Years After the Original Cohort
    Poster J. Mikhael Pomalidomide Celgene

    Monday
    6:00 PM - 8:00 PM
    Hall GH 3963
    Pomalidomide and Dexamethasone in Relapsed Myeloma: Results of 225 Patients Treated in Five Cohorts Over Three Years.
    Oral M. Lacy Pomalidomide Celgene

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
CELG
88.40+1.74(+2.01%)10:24 AMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.